CORRECTED: Rival Drug Didn't Infringe Genzyme's Arthritis Patent: Jury
The jurors said Seikagaku's recently approved Gel-One product — distributed in the U.S. by Zimmer — didn't infringe Genzyme's patent. The jury also said that several of the patent's claims were invalid due to obviousness.
The decision marks a sharp reversal for Genzyme, coming after the Sanofi SA subsidiary secured a preliminary injunction on sales...
To view the full article, register now.